Seeking Alpha
View as an RSS Feed

Stephen Simpson, CFA  

View Stephen Simpson, CFA's Articles BY TICKER:
A, AA, AAOI, AAUKY, AB, ABB, ABT, ACE, ACGL, ACHN, ACI, ADES, ADI, ADM, ADTN, AEIS, AEO, AEP, AER, AES, AET, AEZS, AFRVY, AGCO, AGII, AGRO, AGXXF, AHCHY, AHL, AIMC, ALB, ALCO, ALGN, ALIAF, ALK, ALKS, ALLRF, ALNY, ALPMY, ALSN, ALTR, ALU, ALXN, AME, AMED, AMGN, AMRN, AMSG, AMX, ANFI, ANGO, ANR, ANTM, API, APNHY, APTO, AQPTY, ARAY, ARC, ARCB, ARCO, ARIA, ARNA, ARQL, ARUN, ARWR, ASOMY, ATHN, ATLKY, ATML, ATRC, ATSG, ATU, AUDC, AUXL, AV, AVD, AVEO, AVGO, AWH, AXAHF, AXAHY, AXAS, AXLL, AZN, AZPN, AZSEY, BA, BABY, BAC, BAK, BAM, BAP, BAS, BASFY, BAX, BBG, BBT, BBVA, BCEI, BCR, BDX, BEBE, BELLY, BIIB, BIO, BIOD, BIP, BLERF, BLUE, BMRN, BMTI, BMY, BP, BPMUF, BPOP, BRCD, BRCM, BRFS, BRK.B, BRKR, BRSS, BSFT, BSMX, BSX, BTE, BTU, BWA, C, CA, CACI, CAM, CAT, CAVM, CBD, CBI, CBSH, CBWBF, CCDBF, CCLAY, CDGXY, CDXC, CELG, CEO, CFN, CFX, CHEUY, CHKP, CIEN, CIG, CJES, CLD, CLDX, CLLDY, CLQMF, CLVS, CMA, CMI, CMPR, CNAT, CNH, CODI, COG, COO, COP, CORE, COV, CPA, CPHD, CPN, CPPMF, CR, CRESY, CRHKY, CRS, CRWS, CSCD, CSCO, CSFL, CSII, CSUAY, CVGI, CVGW, CVV, CVX, CX, CYBX, CYCC, CYNI, CZZ, DAN, DBSDY, DCIN, DCM, DD, DE, DGI, DHR, DIIBF, DIS, DNDN, DNR, DNSKY, DOV, DRC, DRQ, DUSA, DVN, DVR, E, EAC, ECTE, EEFT, EEP, EEQ, EGBN, ELGX, ELN, ELP, EMC, EMN, EMR, ENDP, ENH, ENOC, ENSG, ENTG, EONGY, ESPGY, ESSX, ET, ETE, ETN, ETP, ETRM, EVAC, EW, EXAS, EXEL, EZPW, FARM, FAST, FCE.A, FCE.B, FCFS, FCX, FDML, FEIC, FET, FF, FFIV, FHN, FHNIY, FIRE, FITB, FLIDY, FLOW, FLY, FMC, FMX, FNERF, FNSR, FNV, FOLD, FORM, FQVLF, FRAN, FRCOY, FRX, FSII, FSM, FST, FSUGY, FTNT, FUL, GBX, GCTAY, GDOT, GE, GELYY, GGB, GHM, GILD, GLAD, GLDD, GLEKY, GLF, GLNCY, GLPW, GLT, GLW, GMAN, GMED, GMELY, GNKOQ, GNMK, GNNDY, GNRC, GNW, GPN, GRC, GRCLF, GRH, GSIT, GSK, GTLS, GTOMY, GTXI, HAL, HBHC, HBI, HBM, HDS, HELE, HIG, HII, HKMPY, HLF, HLUYY, HLX, HMRTY, HNZ, HOCPY, HOGS, HOLI, HOLX, HON, HP, HPY, HRC, HRL, HSBC, HSC, HSP, HTWR, HURC, HUWHY, HW, HXGBY, HXM, HYPMY, IART, IBKC, ICL, ICPT, ICUI, IDIX, IIIN, IIVI, ILMN, IMGN, IMKTA, IMPUY, IMPV, ING, INGIY, IOSP, IPGLF, IPGP, IPSEY, IR, IRWD, ISRG, ITMN, ITOCY, ITRI, ITUB, ITW, IVNYY, JCI, JNJ, JOY, JPM, JRCCQ, K, KDN, KEG, KEX, KGC, KLAC, KMG, KMTUY, KNDI, KOG, KOP, KPELY, KRA, KRFT, KUKAY, LABL, LAWS, LAYN, LBTSF, LECO, LH, LHCG, LHUAY, LIOX, LLTC, LLY, LMIA, LMNR, LMNX, LNCR, LND, LNVGY, LPDX, LPX, LSI, LSTMF, LUKOY, LXRX, LYSDY, LZAGY, MAKO, MAOIF, MASC, MASI, MCD, MCHP, MDCA, MDCI, MDLZ, MDRX, MDT, MDVN, MEAS, MED, MET, MGJCL, MIC, MIDD, MIICF, MKC, MLKKF, MLNX, MLR, MMM, MMP, MMSI, MNK, MNTX, MOCO, MON, MOS, MR, MRK, MRLN, MRVL, MSCC, MSFT, MSM, MT, MTB, MTGRF, MTL, MTNOY, MTRN, MTRX, MTSC, MTSN, MTW, MWA, MXIM, MXWL, MYL, NAV, NBHGY, NBIX, NBL, NCFT, NCR, NCS, NEOG, NFX, NGVC, NKTR, NOK, NP, NPO, NPSP, NRG, NRP, NSLP, NTAP, NTCT, NTP, NUACF, NUAN, NUE, NUVA, NVDQ, NVEC, NVO, NVS, NWFFF, NYRSY, OA, OAS, OCIR, ODFL, OGZPY, OII, OKS, OMAB, OMER, OMG, OMI, OMVKY, ONNN, ORAN, OSK, OSUR, OVTI, OXY, OZRK, PAA, PAAS, PAC, PACB, PALAY, PANW, PAY, PB, PBF, PBR, PCL, PCTI, PCXCQ, PDCE, PDCO, PDMDF, PEP, PF, PFE, PG, PGEM, PH, PHG, PHMD, PICO, PKD, PKX, PLL, PLOW, PMCS, PMTI, PNC, POL, POOL, POST, POT, POWR, PPCYY, PRAA, PRIM, PRTA, PRX, PTCT, PTR, PVA, PVD, PVTB, PWAV, PXGYF, QBCRF, QRVO, QSFT, RAVN, RCPT, RDWR, RE, RES, RGLD, RHHBY, RIG, RIGL, RIO, RKT, RNR, ROC, ROCM, ROP, RPM, RRC, RSTI, RTOXY, RVBD, RXN, RYN, SAN, SANW, SASR, SBMRY, SCGLY, SEIGF, SEPJY, SFL, SGEN, SGYP, SHG, SHPG, SHS, SID, SIEGY, SKH, SKM, SLAB, SLCJY, SLG, SLGN, SLNCF, SLTM, SLW, SLXP, SNCR, SNHY, SNMX, SNV, SNY, SPB, SPLK, SPN, SPNC, SPW, SSH, SSI, ST, STAR, STB, STCK, STJ, STLD, STO, STWRY, SULZF, SUMR, SURG, SWI, SWK, SWN, SYK, SYRG, TAM, TBNGY, TC, TCB, TCK, TDW, TEAR, TECH, TEN, TEVA, TEX, TFX, TGB, TIBX, TIS, TITN, TKC, TKMR, TKPPY, TLM, TLP, TMK, TMO, TMOAY, TNGO, TOT, TPLM, TRGT, TRIB, TRNX, TRUMY, TSM, TTM, TTNDY, TUWOY, TWGP, TWI, TWIN, TX, TYEKF, TYPE, UFPI, UMPQ, UNCFF, UNFI, UNH, UNT, UPI, UPL, URG, USAP, USB, UTEK, UTMD, UTX, V, VALE, VDNRF, VE, VEGPF, VHI, VICL, VIVHY, VIVO, VLEEY, VMW, VOCS, VOLC, VRX, VVUS, WAB, WCC, WEX, WFC, WFT, WIBC, WLFC, WLL, WMB, WMGI, WRB, WY, X, XCRA, XL, XLNX, XNPT, XOM, XPO, XRAY, XYL, YAMHF, YARIY, YRCW, YZC, ZION, ZIOP, ZMH, ZOLL
  • Receptos Shopping For A Partner With Strong Data In Hand
       • Thu, Jan. 15 RCPT 6 Comments

    Summary

    • Early-stage clinical data has positioned '1063 as a true potential blockbuster that may address multiple sclerosis, ulcerative colitis, and Crohn's disease - all $1B+/year potential markets.
    • Investors should look for more details on the TOUCHSTONE ulcerative colitis trial in February and later in 2015.
    • Receptos could be an attractive takeover candidate, but a fair value of $140-$141 argues for its standalone merits today.
  • JPMorgan Chase Once Again Fails To Inspire
    Editors' Pick • Wed, Jan. 14 JPM 5 Comments

    Summary

    • Loan growth was nice to see, but ongoing NIM erosion and less expense leverage than hoped for set the stage for another disappointment in core operating profits.
    • Higher capital requirements may prompt management to consider a breakup, but the on-the-ground impact of these rules might not be as large as it first appears.
    • Long-term ROE and near-term ROTCE both support a fair value in the mid-$60s, though large banks may remain limited by weak near-term interest rate momentum.
  • XenoPort Prepping For Key Data In 2015
       • Wed, Jan. 14 XNPT 6 Comments

    Summary

    • XenoPort is making progress with its Horizant sales effort, but it is still an uphill climb to make this into a truly valuable product for a company of XenoPort's scale.
    • XenoPort's '829 is the real key to further upside - strong results from a Phase II psoriasis study later this year could potentially put two $15B+ markets into play.
    • Even with low odds of approval/commercialization for '829, XenoPort offers some upside today, and a successful Phase II psoriasis trial outcome could unlock significant upside.
  • Celldex Therapeutics Still Building Its Immuno-Oncology Story
       • Wed, Jan. 14 CLDX 22 Comments

    Summary

    • Celldex appears on track to file for approval of rindopepimut in EGFRVIII-positive glioblastoma, and a change to the pivotal study of glembatumumab in breast cancer shouldn't cause too much worry.
    • Celldex seems to be overlooked as a platform play in immuno-oncology, and varlilumab could factor significantly in future combo therapies.
    • A risk-adjusted assessment of Celldex's portfolio would seem to support a fair value of about $33.
  • With The Tornier Deal On Track, Wright Medical Will Be Busy
       • Wed, Jan. 14 WMGI, TRNX Comment!

    Summary

    • Wright Medical shares have underperformed after announcing its intention to merge with Tornier in a merger of near-equals.
    • The merger proxy supports the criticism that Wright Medical is paying up, but Tornier can add valuable scale, growth in upper extremities, and a better long-term platform for Augment sales.
    • Contributions from Augment are a major unknown today, but can support a fair value into the mid-$30's.
  • Ultratech's Order Outlook Is Murky At Best
       • Tue, Jan. 13 UTEK 1 Comment

    Summary

    • Ongoing delays in orders tied to the 14nm/16nm cycle have sapped Ultratech's revenue and profit outlook, as well as its credibility with the Street.
    • Order timing related to yield issues may not be the biggest problem for Ultratech, as rumors still swirl that rivals like Screen and Mattson have gained share with Ultratech customers.
    • Ultratech's fair value may be between $19 and $26, but strong orders are a must-have for the stock to head higher.
  • The New And Improved Alcoa Showing Its Mettle
    Tue, Jan. 13 AA 1 Comment

    Summary

    • Alcoa beats expectations once again, helped by ongoing reductions in its smelting and refining costs.
    • Next quarter's guidance for the downstream operations was weaker than expected, but the automotive and aerospace OEM markets are meaningful higher-margin growth opportunities over the next five years.
    • Alcoa still looks undervalued using a long-term average multiple, but commodity price risk is still relevant to half of the business.
  • M&A Could Add Even More Pop To SABMiller
       • Tue, Jan. 13 SBMRY Comment!

    Summary

    • 2015 is likely to see even more rumor, speculation, and actual deals in the beer space as global players seek scale, operating leverage, and exposure to volume growth markets.
    • SABMiller is seeing a lull in organic volume growth, but the company is well-placed to benefit from long-term consumer spending growth in Asia, Africa, and Latin America.
    • SABMiller seems fairly valued today on its own merits (assuming mid-single digit revenue growth and further FCF leverage), but M&A activity could drive more value either as buyer or seller.
  • Global Payments Continues To Acquire And Process Growth
       • Tue, Jan. 13 GPN Comment!

    Summary

    • Global Payments has been delivering quarters ahead of Street expectations, as direct sales, integrated payment solutions, and solid share in several foreign markets deliver better growth.
    • With rivals like First Data and Vantiv, integrated payments will be no less competitive a market, but it does offer much better margins than the conventional ISO business.
    • Global Payments seems fairly valued today unless/until the company can prove that it can maintain a higher base level of revenue growth and/or more margin leverage.
  • Orders, Revenue, And Margins Continue To Expand At Hurco
       • Mon, Jan. 12 HURC 4 Comments

    Summary

    • Hurco delivers double-digit growth in revenue and orders, complemented by good margin leverage.
    • U.S. manufacturing activity appears to be improving, but the health of the German manufacturing sector is looking less robust.
    • Mid-single digit revenue growth and modest FCF leverage can support a fair value in the mid-$40s.
  • AngioDynamics Still Looking For Inflection
       • Sat, Jan. 10 ANGO Comment!

    Summary

    • AngioDynamics posted a respectable fiscal second quarter, but overall revenue growth still needs to accelerate from here.
    • BioFlo and AngioVac are the company's best opportunities for driving incremental growth, but it is going to take time to build the businesses in the face of large competitors.
    • AngioDynamics doesn't really work from a DCF perspective without high single-digit revenue growth, but an EV/revenue approach is more forgiving and supports a fair value above $21.
  • Strong Soy And A Deep Pipeline Supports Monsanto
       • Sat, Jan. 10 MON 1 Comment

    Summary

    • Monsanto started the fiscal year off strong, but concerns remain that weak pricing will reduce corn and soy acreage.
    • Looking past the next couple of years, Monsanto has a deep pipeline that should generate the yield/productivity improvements necessary to maintain strong pricing.
    • Competition is a risk in Latin America, but 6% long-term revenue growth can support a fair value in the mid-$120's.
  • Amidst Macro Worries, MTN Group Can Still Outperform
       • Fri, Jan. 9 MTNOY 4 Comments

    Summary

    • MTN Group shares have underperformed on worries about regulation in Nigeria, competition in South Africa, and more general concerns about currency, macroeconomics, and politics.
    • MTN Group is responding with more intelligent pricing/promotion activity in South Africa, patience in Nigeria and Iran, and a more concerted effort to cut costs and promote value-added services.
    • Long-term revenue growth of 7% can support a fair value of $21 with forex movements a key unknown.
  • Neurocrine Biosciences Starts A Data-Rich Year On The Right Foot
       • Fri, Jan. 9 NBIX Comment!

    Summary

    • AbbVie announces positive efficacy data from Neurocrine's Elagolix in a Phase III study of endometriosis-related pain.
    • Investors will have to wait a bit, but additional data releases in 2015 on Elagolix in uterine fibroids and the SOLSTICE endometriosis study are coming.
    • Additional data on '854 in tardive dyskinesia and Tourettes can add meaningful per-share value.
    • Neurocrine isn't cheap on the basis of my current assumptions, but additional positive news could add over $10/share to the fair value.
  • MSC Industrial Continues To Skid
       • Fri, Jan. 9 MSM 3 Comments

    Summary

    • MSC Industrial underwhelms with fiscal first quarter results and disappoints with guidance for the next quarter.
    • With executive departures, ongoing downward revisions, and unimpressive results from the large CCSG acquisition, management needs to reestablish credibility and restore faith in the long-term growth strategy.
    • MSC Industrial shares do still appear to be undervalued, but that value cannot withstand ongoing "miss and lower" quarters.
  • Turkcell: Twists And Turns Continue
       • Wed, Jan. 7 TKC Comment!

    Summary

    • Two large shareholders continue to butt heads, increasing the odds that the Turkish government will have to step in to declare an annual meeting (where dividends can be declared).
    • Actual operating results have been better than expected, with gains in higher value postpaid mobile service and mobile and fixed line broadband.
    • Turkcell doesn't seem to get its full and fair due from the market, but the behind the scenes drama means these shares aren't suitable for all investors.
  • Execution And Purchasing Increasingly Important To PRA Group
       • Tue, Jan. 6 PRAA 1 Comment

    Summary

    • PRA Group has seen its collections and purchasing activity remain lackluster, as major sellers of charged-off receivables haven't returned to the market yet.
    • PRA continues to improve its collections efficiency and credit scoring and the acquisition of Aktiv gives the company a chance to deploy capital on a much wider scale.
    • A fair value in the low $70's is still reasonable, but PRA must pick up its purchasing activity for long-term growth and ROE targets to remain credible.
  • Summer Infant Looking To Transition Back To Growth
       • Tue, Jan. 6 SUMR 6 Comments

    Summary

    • Summer Infant has reorganized its management team, its product development, and its sales approach and is looking to drive improved revenue growth and margins.
    • Summer Infant competes with large rivals that enjoy strong brand recognition, but birth rate trends appear to be improving and Summer Infant is refocusing around innovative product development.
    • A standalone value around $4 may not seem compelling, but there is the potential for financial outperformance and Summer Infant could be worth closer to $5 to a buyer.
  • 3M Is Good As Gold ... And Priced Like It
    Mon, Jan. 5 MMM 11 Comments

    Summary

    • Management remains committed to a policy of innovation-centric product development, ROIC maximization, and counter-cyclical long-term investments.
    • 3M has already plucked much of the low-hanging fruit, making it more challenging to see how management can deliver performance that is consistently above present expectations.
    • It is challenging to argue that 3M shares should trade any higher than they do, suggesting underwhelming return potential, albeit with higher-than-average quality and security.
  • Tiny Aptose Biosciences Looks Worth A Closer Look
       • Dec. 30, 2014 APTO 2 Comments

    Summary

    • Aptose has cleaned up its act and is looking to develop its lead drug APTO-253 for the underserved AML market.
    • APTO-253's mechanism of action targets a gene expressed in 90% of AML cases and is linked to a transcription factor believed to regulate cell death.
    • A safe and effective AML drug could address a market worth over $3 billion a year, but Aptose has much to prove in terms of efficacy and safety.
  • Roche Loses A Little Luster Before Year-End
       • Dec. 22, 2014 RHHBY Comment!

    Summary

    • The Phase III MARIANNE study of Kadcyla delivered a major disappointment as this would-be successor to Herceptin failed to show superior efficacy alone or in combination with Perjeta.
    • Roche also announced the end of another Alzheimer's program, casting further doubt on the company's ability to develop new drugs outside of its oncology franchise.
    • Loss of Kadcyla upside suggests Roche is fairly valued today; a decent hold for investors looking for long-term exposure to oncology, but perhaps not as compelling for new investments.
  • Alnylam Pharmaceuticals Continues To Post Encouraging Results
       • Dec. 22, 2014 ALNY 2 Comments

    Summary

    • Good safety data on revusiran and encouraging early efficacy data on AT3 add more value to the Alnylam pipeline.
    • Alnylam now has over 10 identified clinical and preclinical programs treating a range of metabolic, infectious, and rare genetic diseases.
    • Alnylam may be in the early days of establishing a technology platform on par with past biotech success stories and the shares hold value below $110.
  • Economic Worries Weigh On FEMSA
       • Dec. 20, 2014 FMX 1 Comment

    Summary

    • Weak consumer traffic has kept a lid on enthusiasm for FEMSA's OXXO convenience stores, while ongoing worries about Argentina and Venezuela weigh on Coca-Cola FEMSA.
    • FEMSA continues to manage for long-term growth, including adding more services to OXXO stores, expanding the OXXO store footprint, and bulking up new ventures like its pharmacy operations.
    • FEMSA shares look undervalued below $100, but management needs to deliver better traffic numbers from OXXO to get Wall Street's enthusiasm going again.
  • Despite A Reminder Of The Risks, Senomyx Still Has Appealing Potential
       • Dec. 20, 2014 SNMX 9 Comments

    Summary

    • PepsiCo's delay of its commercial launch of products containing Senomyx's sweetness modifier is a reminder of the challenges of transitioning from a research company to a revenue-producing company.
    • Senomyx's self-directed commercialization efforts have gotten off to a slow start, but it can take years for new products to hit the shelves.
    • 2015 will be an important year for Senomyx, as a strong Pepsi launch is vital to the prospects of the stock.
  • The Going's Getting Tougher, But ABB Is Still Going
       • Dec. 19, 2014 ABB 4 Comments

    Summary

    • Sluggish economic trends in Europe and falling oil prices have the sell-side fretting about ABB's ability to meet expectations in 2015.
    • Strong order growth would seem to support management's growth outlook and expectations for the Power Products and Power Systems businesses look pretty washed out.
    • With sentiment against the stock, ABB management is in "show me" mode, but the stock's price today doesn't seem to fairly value relatively modest growth and margin improvement assumptions.
  • Despite A Share Price Slide, Commercial Vehicle's Plan Remains On Track
       • Dec. 19, 2014 CVGI Comment!

    Summary

    • Investors have sold CVGI shares since the summer, as larger concerns about commercial vehicle suppliers intermingle with disappointments from the company's mid-September Analyst Day.
    • Investors seem to be disappointed in guidance calling for 2015 and 2016 to be years of investment and self-improvement rather than years of significant margin improvement and growth.
    • Tying a meaningful portion of the growth plan to agriculture may seem risky, but CVGI's market share targets are actually not so ambitious.
    • CVGI is liable to remain a volatile name given its ongoing turnaround/restructuring efforts and its reliance on cyclical markets, but the shares have value past $9.
  • Philips Looks To Long-Time Laggard Volcano To Perk Up Its Healthcare Biz
       • Dec. 19, 2014 VOLC, PHG 2 Comments

    Summary

    • Philips is paying 3.0x sales to add a procedure-driven seller of cardiology disposables that should offer logical synergies with Philips' existing cardiology imaging and navigation business.
    • Volcano has seen sales growth stagnate on weaker procedure volumes, intensifying competition, and management's strategic missteps.
    • Philips' offer is a fair balance between the potential of the integration businesses and the challenges Volcano was facing as a standalone entity.
  • Better Priorities Leading To Better Outcomes For Broadcom
       • Dec. 18, 2014 BRCM 10 Comments

    Summary

    • Broadcom is turning away from a focus on revenue growth and toward a focus on profitable growth that earns a premium on the cost of capital.
    • New networking products should preserve the company's lead in switching and supply good growth, while handset connectivity risks may be overstated.
    • Turning away from M&A may lead to lower growth expectations and competition will remain fierce but low-to-mid single-digit FCF growth can support a target in the mid-$40s.
  • Lundbeck Continues To Fight To Stand Out
       • Dec. 18, 2014 HLUYY Comment!

    Summary

    • Positive data on drugs like Brintellix and brexpiprazole have been overshadowed by slow marketing ramps and the departure of the CEO for an ethics violation.
    • 2015 will be a critical year for Lundbeck in establishing the viability of Brintellix and other drugs like Northera, as well as getting brexpiprazole to market.
    • The loss of the CEO and significant expecting marketing spending in 2015 ups the risk, but Lundbeck shares could still return 25% to 40% if the launches gain traction.
  • Cyclacel Now An Exercise In Futility
       • Dec. 18, 2014 CYCC 12 Comments

    Summary

    • The data and safety monitoring board for the Phase III SEAMLESS study has informed the company that sapacitabine is unlikely to show an efficacy benefit in treating elderly AML patients.
    • Continuing the SEAMLESS study is a questionable use of capital and Cyclacel's remaining pipeline doesn't inspire confidence.
    • The slim chances of sapacitabine in AML and MDS are outweighed by the prospects that immuno-oncology drugs will prove more effective.
    • At this point, Cyclacel is just a low-quality broken biotech with only speculative trading value.
  • Ghosts Of Business Problems Past Visit Accuray Again
       • Dec. 17, 2014 ARAY 6 Comments

    Summary

    • Lack of communication with the Street set Accuray up for a very disappointing order report, as older orders age out of the book.
    • Management has made meaningful progress with the sales effort, including an exclusive relationship with Premier, and the introduction of a multi-leaf collimator should spur orders in fiscal 2H'15.
    • SBRT appears to offer meaningful advantages over IMRT/IGRT in certain cancer cases, and harnessing increased adoption of SBRT could take Accuray to $1 billion in revenue down the line.
  • Manitex Still Hopes To Grow Past The Crane Wreck
       • Dec. 17, 2014 MNTX Comment!

    Summary

    • Weak crane demand has sapped large OEMs like Terex and Manitowoc, as well as smaller OEMs like Manitex.
    • Manitex continues to build out the business, with the most recent transaction adding Terex's struggling ASV operations.
    • Weak oil prices threaten a major Manitex end market, but internal integration/improvement efforts can still generate value, as can a recovery in infrastructure, construction, utility, and transportation markets.